ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

IDIX (MM)

24.50
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
(MM) NASDAQ:IDIX NASDAQ Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 24.50 0.00 01:00:00

Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences

23/04/2007 10:05pm

PR Newswire (US)


(MM) (NASDAQ:IDIX)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more (MM) Charts.
CAMBRIDGE, Mass., April 23 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) announced today that Idenix management will present a corporate overview at the upcoming Deutsche Bank 32nd Annual Healthcare Conference on Wednesday, May 2nd at 1:45 p.m. (EDT) in Washington, D.C. and the 2007 Morgan Stanley Global Healthcare Unplugged Conference on Thursday, May 3rd at 10:15 a.m. (EDT) in Key Biscayne, FL. The live and archived webcasts of the company presentations can be accessed under "Calendar of Events" in the Idenix Investor Center at http://www.idenix.com/ . Please log in approximately 5-10 minutes before the events to ensure a timely connection. The archived replays will be available on the Idenix website for two weeks following the conferences. The company presentations will be available for download in PDF format in the "Investor Presentations" section of the Investor Center immediately following the presentations. About Idenix Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by hepatitis B virus, hepatitis C virus and human immunodeficiency virus (HIV). For further information about Idenix, please refer to http://www.idenix.com/ . Idenix Pharmaceuticals' Contacts: Media: Teri Dahlman (617) 995-9905 Investors: Amy Sullivan (617) 995-9838 DATASOURCE: Idenix Pharmaceuticals, Inc. CONTACT: Media, Teri Dahlman, +1-617-995-9905, or Investors, Amy Sullivan, +1-617-995-9838 Web site: http://www.idenix.com/

Copyright

1 Year (MM) Chart

1 Year (MM) Chart

1 Month (MM) Chart

1 Month (MM) Chart

Your Recent History

Delayed Upgrade Clock